befetupitant befetupitant befetupitant (ro67-5930) is a drug developed by hoffmann-la roche which acts as a potent and selective antagonist for the nk1 receptor. it was originally developed as a potential antiemetic drug, though development was ultimately discontinued after a related drug netupitant was deemed to be more suitable for clinical development. befetupitant has however continued to be researched for other possible applications such as treatment of corneal neovascularization. befetupitantclinical dataatc codenoneidentifiers iupac name 2--n,2-dimethyl-n-propanamide cas number290296-68-3 ypubchem cid6450815chemspider4953365uniirsh7ndi7micomptox dashboard (epa)dtxsid90183270 chemical and physical dataformulac29h29f6n3o2molar mass565.560 g·mol−13d model (jsmol)interactive image smiles cc1=cc=cc=c1c2=cc(=nc=c2n(c)c(=o)c(c)(c)c3=cc(=cc(=c3)c(f)(f)f)c(f)(f)f)n4ccocc4 inchi inchi=1s/c29h29f6n3o2/c1-18-7-5-6-8-22(18)23-16-25(38-9-11-40-12-10-38)36-17-24(23)37(4)26(39)27(2,3)19-13-20(28(30,31)32)15-21(14-19)29(33,34)35/h5-8,13-17h,9-12h2,1-4h3key:zgnplcmmvkcthm-uhfffaoysa-n